> ## Content Index
> Fetch the complete content index at: https://psychedelicmentalhealth.net/llms.txt
> Use this file to discover other available public pages before exploring further.

# Spotlight: New and emerging pharmacologic treatments for MDD (Uyar, et al, 2025)
- URL: https://psychedelicmentalhealth.net/ketamine-major-depressive-disorder-2025/
- Published: 2025-08-27T19:24:00.000Z
- Updated: 2025-08-27T19:24:00.000Z
- Description: "Clinical trials have demonstrated the ability of ketamine to quickly reduce symptoms, particularly in treatment-resistant cases, with effects noticeable within hours and lasting several days post-administration."
- Author: Michael DeMarco, PhD
- Tags: ketamine, depression, ketamine research, psychedelic research

[New and emerging pharmacologic treatments for MDD - PubMedMajor depressive disorder (MDD) presents a significant global health challenge, characterized by a high prevalence and significant impact on quality of life. Traditional antidepressants fall short in terms of efficacy and onset speed, up to 60% of patients. This review delves into the new and emergi …![](https://storage.ghost.io/c/61/a8/61a8484e-df24-47fb-903c-d012ff10c983/content/images/icon/favicon-192-55.png)PubMedAslihan Uyar![](https://storage.ghost.io/c/61/a8/61a8484e-df24-47fb-903c-d012ff10c983/content/images/thumbnail/pubmed-meta-image-v2-54.jpg)](https://pubmed.ncbi.nlm.nih.gov/40859935/)

(2025): ****New and emerging treatments in MDD have centered on different neurobiological pathways than the traditional monoaminergic systems. Ketamine and its enantiomer, S-ketamine, have been highlighted for their rapid antidepressant effects, which act through non-competitive** ***N** **\-methyl-d-aspartate (NMDA) receptor antagonism and other pathways involving synaptic plasticity.**